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Purpose: Dose escalation of non-small cell lung cancer is 
typically limited by increasing risk of severe adverse events, 
including radiation pneumonitis (RP). Recent studies have 
demonstrated a relationship between a CBCT derived marker 
(CDM) and lung density changes on follow up imaging. This study 
investigates the relationship between a density-based CBCT 
image marker and symptomatic radiation pneumonitis. 
Methods and Materials: CDMs were extracted for NSCLC patients 
treated definitively (> 54 Gy) with fractionated radiotherapy 
between 2011 and 2013. The CDM was defined as the proportion 
of normal lung voxels receiving 20-60 Gy that demonstrated an 
intensity increase between the first and tenth fraction CBCT, as 
previously described. Only voxels with an intensity change 
greater than a defined noise threshold were included. All images 
were registered into a common volume using an intensity-based 
deformable image registration algorithm in the Elastix toolbox. 
All other image analysis was implemented in Matlab 2010b. RP 
was determined from prospective clinical records and reviewed 
retrospectively from the electronic patient record, as scored by 
the treating oncologists at follow up visits as per CTCAE v 4.0. 
Dosimetric parameters extracted included mean lung dose and 
volume of lung receiving 20 Gy (V20). Correlation of dosimetric 
parameters and the CDM to RP events was assessed by 
Spearman’s rank correlation coefficient and multivariate 
logistical regression.  
Results: After excluding patients without dose or CBCT objects, 
65 patients were identified and CDM extracted. In those patients, 
the prescription dose range was 54-74 Gy, mean lung dose range 
was 13-23 Gy and V20 range was 3.4 – 38%. The number of voxels 
with an intensity change greater than the noise level ranged from 
0-74.5% (mean 5.3%). Symptomatic RP (≥ Grade 2) occurred in 
26.1% of patients of these patients. Spearman's rank correlation 
demonstrated significant association between mean lung dose 
and V20 with symptomatic radiation pneumonitis (p = 0.044 and 
p = 0.036 respectively), whereas the CBCT marker was not 
correlated (p = 0.609). Univariate logistic regression of mean 
lung dose and the CBCT marker was not significantly correlated 
with symptomatic RP (p = 0.090 and p = 0.821 respectively). 
Multivariate logistic regression with mean lung dose and the 
CBCT marker was not significant (p = 0.077). 
Conclusions: One previously described density-related CDM was 
not correlated with RP in this dataset. Further research is 
required to characterize the role of imaging markers in 
predicting radiation pneumonitis. 
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Purpose: Total body irradiation (TBI) is used prior to bone 
marrow transplantation as part of the conditioning regimen in 
selected patients. A linear accelerator based technique has been 
used at our treatment centre, between 2004 and 2015. 
Compensators to account for missing tissue in the head and neck 
and lower leg regions, as well as a lung attenuator for internal 
inhomogeneity resulting from low density lung tissue are 
routinely used. Dose variation within ten percent of the 
prescribed midplane dose is considered acceptable. The purpose 
of this study was to determine whether dose variation was within 
acceptable limits for patients who underwent TBI. 
Methods and Materials: Following chart review, 129 patients 
between June 2004 and August 2015 who received TBI in six 
fractions were included in this study. Patients receiving single 
fraction treatment were excluded. MOSFET dosimetry was used 
to measure surface dose at 4 or 5 locations when patients 
received the first fraction of TBI. Dosimetry was repeated during 
the second fraction for any site with variation greater than ten 
percent, or when MOSFET position was noted to have shifted. 
Statistical analysis on patient data, diagnosis and dosimetry 
measurements was carried out using a Microsoft Excel 
spreadsheet. 
Results: Of the 129 patients who met the inclusion criteria, 50 
were diagnosed with AML, 30 with ALL and 11 with CML. The rest 
of the patients were diagnosed with lymphoma or MDS. The mean 
percent variation in dosimetry ranged between 3.5% and 8.3%. 
The highest variation was found in cheek dosimetry. A high 
percentage of dosimetry readings (85.5%) were within the 
acceptable range. The highest number of individual readings 
outside ± 10% was found at the leg. The median percentage 
variation was low (3.3% to 5.1%) depending on location.  
Conclusions: A retrospective analysis of 129 patients was carried 
out for the period 2004 to 2015. The analysis shows acceptable 
variation in dosimetry within ten percent. The top three 
locations with greatest variation were the cheek, the chest, and 
the leg respectively. We conclude that linear accelerator 
delivered TBI at our centre meets the acceptable limits of dose 
variation for 129 patients over a 10-year period. The reasons for 
variation at particular sites will be discussed. 
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Purpose: The CanMEDS framework defines the core physician 
roles on which specialist medical education in Canada is based. 
The revised CanMEDS 2015 framework introduces “Leader” as a 
new CanMEDS competency. In this study, we identified 
leadership training gaps in radiation oncology residency and 
developed a focused curriculum specific to radiation oncology to 
meet this new competency requirement. 
Methods and Materials: A questionnaire was administered to 
senior residents and recent graduates of a radiation oncology 
residency training program in Canada. Qualitative data regarding 
staff and resident leadership responsibilities, leadership training 
in residency, and any perceived gaps in residency leadership 
training were gathered. Based on identified educational needs, 
a leadership curriculum was developed and administered to 
current radiation oncology residents. 
Results: Following analysis of the qualitative questionnaire data, 
three modules were designed to address the identified gaps in 
radiation oncology residency leadership training. Specifically, 
the modules were developed to increase knowledge and 
execution of different leadership styles, develop skills in 
teamwork and negotiation, and recognize specific leadership 
qualities within each resident. 
Conclusions: In this study, we identified important leadership 
competencies for radiation oncology residents as they transition 
into fellowship and junior consultant positions. To our 
knowledge, this is the first description of a radiation oncology-
specific leadership curriculum designed to meet these needs.  
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Purpose: The use of 3D printing technology to create precise 
anatomical models is well documented. These models are used 
by surgeons to better plan upcoming operations and to save 
valuable operating room time. They are also used to educate 
other members of the health care team, such as residents, 
medical students and nurses. However, the use of these 
anatomically accurate models to educate patients in the clinical 
setting has been underutilized. At our centre, we are using 3D 
printer technology to generate accurate clinical models of 
mandibles. Our objective is to use these models to better 
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educate and prepare head and neck cancer patients for 
upcoming surgery where manibulectomy is part of the surgical 
procedure. This has been used to educate three consecutive 
patients.  
Methods and Materials: For each patient, detailed anatomy of 
the mandible was obtained via CT images which were already 
required for patient staging and treatment. Images were 
segmented (3D Doctor, Able Software) and the resulting model 
was exported as an STL file to software controlling the printer 
(Repetier-Host), converted to gcode (Slic3r) and printed on a 
consumer-Grade 3D printer (MakerGear, M2). To improve quality, 
a slow print speed of about 30 mm/second was used. A layer 
thickness of 0.3 mm resulted in reasonable print times. 
Results: We were able to create a precise and detailed life-size 
model of the patient’s mandible for three patients. Each model 
included minute normal anatomy as well as the defect created 
by the tumour.  
The surgeon involved was able to use the models during clinical 
visits to educate the patients. He was able to better illustrate 
his plan to perform a mandibulectomy to fully remove the 
tumour and surrounding healthy bone. He was also able to show 
the supportive, metal reconstruction plate which would be 
moulded to fit the mandible. In these cases, each patient was 
able to give suggestions based on personal preferences and their 
new understanding of the anatomy displayed on the model. This 
resulted in a decrease in patient anxiety. It also led to a modest 
change in surgical planning and management. The models were 
subsequently used to customize the reconstructive plates. 
Conclusions: The use of 3D printing technology to create precise 
anatomic models in order to educate patients is a novel and 
promising approach. When patients are able to visualize their 
own anatomy and the anatomy of an invading tumour, it allows 
them to be more involved in their own care. There is a decrease 
in anxiety and in some instances, it can even lead to technical 
changes in management. Although 3D printing has already been 
used to save valuable operating room time and in the medical 
education of other health care professionals, we found that it 
can be effectively used as a valuable, patient education tool. 
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Purpose: Radioactive iodine (RAI) dose for early differentiated 
thyroid cancer (DTC) has decreased from 100mCi to 30mCi. There 
is little long-term data to determine the effect, if any, on disease 
recurrence. Our analysis aims to identify clinicopathologic 
factors associated with disease recurrence in DTC. 
Methods and Materials: Patients diagnosed between 1996 and 
2008 with Stage I-II DTC (papillary and follicular) who had 
undergone surgical resection followed by RAI and had been 
followed for five years with ultrasound, thyroglobulin, and whole 
body thyroid scans were eligible for analysis. We identified 219 
eligible patients from the database. Patients were stratified into 
two groups by initial RAI dose (≤ 50 versus > 50 mCi). Recurrence 
was defined as an elevated stimulated thyroglobulin 
(biochemical recurrence) or biopsy-proven disease. Test for 
significant differences between the survival and relapse curves 
was done using the log-rank test. Survival and relapse curves 
were calculated using the Kaplan-Meier method. 
Results: A greater proportion of patients in the high dose RAI 
group had extrathyroidal extension (ETE) (52.0% versus 24.8%, p 
= 0.001). Groups did not differ otherwise in baseline 
characteristics. Patients who recurred more frequently had ETE 
(43.7% versus 21.9%, p = 0.003) and lymph node (LN) metastases 
(74.7% versus 38.3%, p < 0.001) at diagnosis. Tumour size, 
multifocality, vascular invasion, patient age and gender did not 
predict for recurrence. On multivariate analysis, LN metastases 
at diagnosis predicted for local and distant recurrence (HR 2.67, 
1.17-6.05). Female gender (HR 4.08, 1.04-16.05) and initial dose 
≤ 50 mCi (HR 6.30, 1.30-30.55) predicted for local recurrence. 
Median time to recurrence was shorter in patients receiving an 
initial dose ≤ 50 mCi (23.2 versus 47.6 months, p < 0.001). Median 
survival time did not differ between dose groups (105.8 versus 
114.1 months, p 0.773). On multivariate analysis, patients 
treated with initial dose ≤ 50 mCi who had ETE and LN metastases 
at diagnosis were more likely to recur (p = 0.004). Patients with 
both risk factors had a median time to recurrence of 25.2 months 
(≤ 50 mCi) versus 120.9 months (> 50 mCi), p = 0.04.  
Conclusions: Patients treated with ≤ 50 mCi had a significantly 
shorter mean time to disease recurrence. In patients treated 
with ≤ 50 mCi, ETE and lymph node metastases at diagnosis 
predicted for recurrence. Patients presenting with these risk 
factors may require an initial RAI dose > 50 mCi. Further analyses 
are required to confirm these findings.  
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Purpose: The radiotherapy volumes in anaplastic (ATC) and 
differentiated thyroid carcinomas (DTC) are controversial, 
particularly with respect to the necessity of prophylactic nodal 
treatment. 
Methods and Materials: We retrospectively examined the 
patterns of failure following post-operative intensity modulated 
radiation therapy in 30 DTC and five ATC patients treated 
radically from 2006-2012. Radiotherapy volumes routinely 
included the thyroidectomy bed, level III-VI, with level II and V 
partially included, for both ATC and DTC. Patients who received 
primary radiotherapy, patients treated for recurrent disease, 
and patients who received palliative radiotherapy were excluded 
(n = 245). No patient received concurrent chemotherapy. CT 
scans were rigidly registered with the original radiotherapy plans 
and dose to the recurrence volume was determined. Recurrences 
were in-field if > 95% received 95% of the prescribed dose, out-
of-field if < 20% received 95% of the dose, and marginal 
otherwise. Overall survival rate was calculated using the Kaplan-
Meier method. The cumulative incidence rates of locoregional 
recurrence and distant recurrence were calculated with death as 
the competing risk. 
Results: Median radiotherapy dose was 52Gy in 20 fractions for 
ATC (range: 40 Gy/16 – 60 Gy/40 BID) and 66 Gy in 33 fractions 
for DTC (range: 60 Gy/30 – 66 Gy/33). Positive margins and 
extracapsular extension were present in all ATC patients, and in 
80% and 93% of DTC patients, respectively. 4/30 DTC patients 
developed regional recurrence: one in-field (level II/III) and 
three out-of-field (all in level II). Two patients underwent 
salvage neck dissections. Six patients developed metastatic 
disease. There were no local recurrences. Five-year overall 
survival, locoregional recurrence, and distant recurrence were 
93%, 17%, and 23%, respectively. Among ATC cases, five out of 
five recurred at seven sites: two were local, and five regional: 
one marginal (intramuscular to the digastric) and four out-of-
field (one retropharyngeal, one in soft tissues near the 
manubrium, and two lateral to the sternocleidomastoid). All ATC 
patients developed lung metastases with a median survival of 1.2 
years. 
Conclusions: In DTC, locoregional recurrence is unusual 
following radiotherapy. Out-of-field DTC recurrences occurred in 
level II, however, increasing treatment volumes to level II must 
be balanced against an expected greater risk of toxicity. 
